As Celgene Corp. made ready to unveil second-quarter earnings Thursday, onlookers were disappointed but not hugely surprised by the firm's disclosure that it would not seek approval in diffuse large B-cell lymphoma (DLBCL) with Revlimid (lenalidomide), due to a miss on the key secondary endpoint of overall survival (OS) in interim results from a phase III trial called REMARC.